Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Multicentric Castleman Disease in Malawi
NCT04585893Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jun 2021
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in multicentric Castleman disease (MCD), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Jun 2021; status: completed.
02
Drugs
rituximab
03
Conditions
multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT04585893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585893.